Sequential versus concomitant administration of docetaxel and gemcitabine as first-line treatment of advanced non-small cell lung cancer (NSCLC):: results of a phase II/III randomised study

被引：0
|
作者：
Manegold, C.
Thatcher, N.
Kortsik, C.
Koschel, G.
Spengler, W.
Mezgar, J.
Schott von Romer, K.
Pilz, L.
机构：
[1] Univ Mannheim, Med Ctr, Chirurg Klin, Mannheim, Germany
[2] Christie Hosp, Dept Clin Oncol, Manchester, Lancs, England
[3] Sankt Hildegardis Hosp, Catholic Clin Ctr, Mainz, Germany
[4] Gen Hosp Hamburg, Dept Lung & Bronchialkunde, Hamburg, Germany
[5] Schillerhohe Hosp Gerlingen, Stuttgart, Germany
[6] St Vincentius Hosp, Med Klin, Karlsruhe, Germany
[7] Thoraxklin, Heidelberg, Germany
[8] German Canc Res Ctr, D-6900 Heidelberg, Germany
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：326 / 326
页数：1
相关论文
共 50 条
  • [41] Docetaxel and gemcitabine combination as first-line treatment in advanced or metastatic non-small-cell lung cancer: A multicenter phase II study
    Costa, A
    Almodovar, T
    Seada, J
    Barata, F
    Teixeira, E
    Queiroga, H
    Pires, S
    [J]. PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2004, : 117 - 120
  • [42] Phase II study of biweekly Gemcitabine and Docetaxel as first line treatment for advanced disease in elderly Non Small Cell Lung Cancer (NSCLC) patients
    Munoz-Langa, Jose
    Sanchez-Hernandez, Alfredo
    Gomez-Codina, Jose
    Esquerdo, Gaspar
    Catot, Silvia
    Macia, Sonia
    Juan, Oscar
    Giner, Vicente
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S700 - S701
  • [43] Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC).: Across
    Domènech, M
    Losa, F
    Blanco, R
    Nogué, M
    Montesinos, J
    Mesía, C
    Gallardo, E
    de Olaguer, JP
    [J]. LUNG CANCER, 2005, 49 : S242 - S242
  • [44] Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC). The ACROSS Study
    Domenech, Montse
    Losa, Ferran
    Blanco, Remei
    Nogue, Miquel
    Montesinos, Jesus
    Mesia, Carles
    Gallardo, Enrique
    Perez de Olaguer, Joaquim
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 177 - 177
  • [45] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Sequential versus standard chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase III randomised trial
    Paesmans, M.
    Berghmans, T.
    Lafitte, J. J.
    Lecomte, J.
    Alexopoulos, C. G.
    Van Cutsem, O.
    Giner, V.
    Efremidis, A.
    Scherpereel, A.
    Sculier, J. P.
    [J]. LUNG CANCER, 2006, 52 : S26 - S27
  • [47] Weekly administration of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC).
    Sun, Y
    Li, J
    Wu, Y
    Li, L
    Gu, L
    Zhang, L
    Wang, J
    Zhang, X
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 698S - 698S
  • [48] Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial
    Radhakrishnan, A.
    Bitran, J. D.
    Milton, D. T.
    Tolzien, K.
    Hallmeyer, S.
    Nabhan, C.
    [J]. JOURNAL OF CHEMOTHERAPY, 2009, 21 (04) : 439 - 444
  • [49] Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Butts, C. A.
    Bodkin, D.
    Middleman, E. L.
    Englund, C. W.
    Ellison, D.
    Alam, Y. Z.
    Pautret, V.
    Weber, M.
    Kreisman, H.
    Shepherd, F. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer:: a phase II trial
    Laack, E
    Mende, T
    Benk, J
    Chemaissani, A
    Scholtze, J
    Lorenz, C
    Niestroy, A
    Dalhoff, K
    Müller, T
    Walter, T
    Dürk, H
    Edler, L
    Hossfeld, DK
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) : 583 - 590
12345